Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

29.11 (USD) • At close June 3, 2025
Bedrijfsnaam Kiniksa Pharmaceuticals, Ltd.
Symbool KNSA
Munteenheid USD
Prijs 29.11
Beurswaarde 2,124,184,849
Dividendpercentage 0%
52-weken bereik 17.38 - 29.71
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sanj K. Patel
Website https://www.kiniksa.com

An error occurred while fetching data.

Over Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a

Vergelijkbare Aandelen

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

1.22 USD

Pharvaris N.V. logo

Pharvaris N.V.

PHVS

17.28 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

0.555 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

6.39 USD

Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD

0.697 USD

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

0.919 USD

Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

5.53 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)